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ABSTRACT 1 
A higher intake of foods rich in flavonoids such as quercetin can reduce the risk of 2 
cardiovascular disease. Enzymatically modified isoquercitrin (EMIQ®) has a bioavailability 3 
17-fold higher than quercetin aglycone and has shown potential cardiovascular disease 4 
moderating effects in animal studies. The present study aimed to determine if acute ingestion 5 
of EMIQ® improves endothelial function, blood pressure, and cognitive function in human 6 
volunteers at risk of cardiovascular disease. Twenty-five participants (12 males, 13 females) 7 
with at least one cardiovascular disease risk factor completed this randomized, controlled, 8 
crossover study. In a random order, participants were given EMIQ® (2 mg aglycone 9 
equivalent)/kg body weight or placebo alongside a standard breakfast meal. Endothelial 10 
function, assessed by flow mediated dilatation (FMD) of the brachial artery was measured 11 
before and 1.5 hrs after intervention. Blood pressure (BP), arterial stiffness, cognitive 12 
function, BP during cognitive stress and measures of quercetin metabolites, oxidative stress 13 
and markers of nitric oxide (NO) production were assessed post-intervention. After 14 
adjustment for pre-treatment measurements and treatment order, EMIQ® treatment resulted in 15 
a significantly higher FMD response compared to the placebo [0.60%, 95% CI: 0.03, 1.17 16 
(p=0.04)]. Plasma concentrations of quercetin metabolites were significantly higher 17 
(p<0.001) after EMIQ® treatment compared to the placebo. No changes in blood pressure, 18 
arterial stiffness, cognitive function, or biochemical parameters were observed.  In this 19 
human intervention study, the acute administration of EMIQ® significantly increased 20 
circulating quercetin metabolites and improved endothelial function. Further clinical trials are 21 
required to assess whether health benefits are associated with long-term EMIQ® 22 
consumption. 23 
 24 
 25 
 26 
 27 
 28 
 29 
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INTRODUCTION: 30 
There is mounting evidence from both cohort studies and clinical trials that an increased 31 
intake of plant foods, specifically those rich in flavonoids, can reduce the risk of 32 
cardiovascular disease (1). Quercetin (in its glycosylated form) is the most commonly 33 
consumed flavonoid compound within the flavonol subclass (2). The main dietary contributors 34 
to quercetin intake include tea, apples, onions, and broccoli (3).  35 
Evidence for the health promoting effects of quercetin comes primarily from animal and in 36 
vitro studies (4). In a randomized-controlled cross-over study of men and women, apples with 37 
skin significantly reduced systolic blood pressure, improved endothelial function and 38 
increased plasma nitric oxide (NO) (5). These apples with skin provided 184 mg of quercetin 39 
and 180 mg of (−)-epicatechin while the apple flesh only (control) provided less than 5 mg of 40 
quercetin and (−)-epicatechin. Previous studies using both pure quercetin aglycone (1095 mg) 41 
(6) and quercetin glucoside supplementation (50 – 400 mg) (7; 8) have shown no effect on 42 
endothelial function. This may be due to in part to the bioavailability of the quercetin 43 
interventions.  44 
Quercetin in foods is usually found in its glycosylated form, with the presence and position of 45 
the sugar moiety influencing the site and extent to which it is absorbed (9). The bioavailability 46 
of quercetin glucosides can be enhanced by enzymatic α-oligoglucosylation of this sugar 47 
moiety (10). Enzymatically modified isoquercitrin (EMIQ®) is a water-soluble glucoside of 48 
quercetin produced by the deglycosylation and subsequent α-oligoglucosylation of rutin (10). 49 
Plasma concentrations of quercetin metabolites have been shown to be approximately 2-3 50 
times higher after the consumption of EMIQ® in comparison to isoquercitrin (quercetin-3-O-51 
glucoside) and its bioavailability is 17-fold higher than that of quercetin (10; 11).  52 
EMIQ® has been shown to suppress the increase in systolic BP observed in spontaneously 53 
hypertensive rats, (12) and decrease oxidative stress in a mouse model of atherosclerosis (13). 54 
EMIQ® is approved in Japan as a food additive and is safe for human consumption. Human 55 
trials carried out over a 12-week period indicate a significant reduction in body fat (14). The 56 
effects of EMIQ® on vascular and cognitive function have yet to be investigated. 57 
Therefore, the aim of the present study was to determine if acute ingestion of EMIQ® 58 
improves endothelial function, blood pressure, and cognitive function in human volunteers at 59 
risk of cardiovascular disease.  60 
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SUBJECTS AND METHODS: 61 
Participants 62 
Twenty-five eligible men and women, aged between 50 and 70 years, were recruited by 63 
newspaper advertisement from the general population of Perth, Western Australia (Figure 1). 64 
These volunteers attended a screening appointment within the University of Western 65 
Australia, School of Biomedical Sciences, located in the Medical Research Foundation 66 
building at Royal Perth Hospital. The screening appointment consisted of an 67 
electrocardiograph, a standard medical history questionnaire, and the measurement of height, 68 
weight, body mass index (BMI) and BP. Finally, a blood sample was taken for measurement 69 
of fasting serum total cholesterol, HDL-cholesterol (HDL-C), triglycerides (TG), LDL-70 
cholesterol (LDL-C), and glucose. Volunteers were included in the study if they had at least 71 
one of the following risk factors for CVD: systolic BP between 120 mmHg and 160 mmHg, 72 
fasting plasma glucose between 5.6 mM and 6.5 mM, total cholesterol between 5 mM and 8 73 
mM or a waist circumference >94 cm for men or >80 cm for women. Exclusion criteria 74 
included a BMI <18 or >35 kg/m2; a systolic BP ≤100 or ≥160 mmHg; a diastolic BP ≤50 or 75 
≥90 mmHg; diagnosed diabetes; fasting plasma glucose concentrations ≥6.5 mmol/L; use of 76 
BP lowering or cholesterol lowering medication; alcohol intake >210 g per week for women 77 
and >280 g per week for men; current or recent (within previous 6 months) significant weight 78 
loss or gain (>6% of body weight); actively trying to lose weight; current or recent (<12 79 
months) smoking; history of cardiovascular or peripheral vascular disease; psychiatric or any 80 
other major illnesses; and women were lactating, pregnant or wishing to become pregnant 81 
during the study. 82 
The study was carried out in accordance with the Declaration of Helsinki and was approved 83 
by the University of Western Australia Human Research Ethics Committee (Approval 84 
number RA/4/1/9260). All participants provided written informed consent before inclusion in 85 
the study. The trial was registered with the Australian New Zealand Clinical Trials Registry 86 
(ACTRN12617001202358). 87 
Study design  88 
This acute, randomized, controlled crossover trial was conducted between September 2017 89 
and June 2018. Participants were required to visit the department three times (one practice 90 
visit and two study visits).  The practice visit involved the completion of a selection of 91 
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cognitive function tests designed to induce cognitive stress (see description below) three 92 
times, in order to control for practice effects and to allow familiarization with procedure. The 93 
practice day data were not included in any analyses. Participants were required to fast for 12 94 
hrs (water allowed ad libitum) prior to each subsequent study visit. These two visits were 95 
separated by at least 7 days to ensure that there were no carry-over treatment effects. 96 
Participants were instructed to have the same meal the night before, not to consume any 97 
alcohol for 24 hrs prior to the visit and not to take any medication or undergo any exercise on 98 
the morning of their visit. Endothelial function was assessed before and 1.5 hrs post-99 
intervention. A blood pressure measurement was taken prior to and every 10 min for 80 min 100 
post treatment. Measurements of arterial stiffness were taken 2 hrs post-intervention. 101 
Participants completed the selection of cognitive function tests 2.5 hrs post-intervention, 102 
during which blood pressure was measured every 2 min. Finally, a blood sample was taken 103 
by venipuncture 3.5 hrs post-intervention. 104 
Intervention 105 
Participants were randomly assigned to one of two treatment orders generated using a 106 
pseudorandom number generator (https://www.randomizer.org/). The EMIQ® was prepared 107 
by San-Ei Gen F.F.I., Incorporated (Osaka, Japan). The active treatment consisted of 4.89 mg 108 
EMIQ® (2 mg aglycone equivalent)/kg body weight (10) plus ½ teaspoon of maltodextrin and 109 
1½ tablespoons of Cottee’s Raspberry flavoured cordial mixed with 250 mL water. The 110 
placebo treatment was ½ teaspoon of maltodextrin and 1½ tablespoons of cordial mixed with 111 
250 mL water. The cordial was used to mask the taste and the colour of the EMIQ®. Both 112 
treatments were given with a standardised breakfast of 2 pieces of white bread and cheese. 113 
Participants and all researchers performing the tests and analysing the results were blinded to 114 
the treatment. 115 
Assessment of endothelial function 116 
In order to assess endothelial function, flow-mediated dilatation (FMD) of the brachial artery 117 
was calculated by a trained ultrasonographer, dedicated to the research protocol and blinded 118 
to the interventions used. Participants were studied in a quiet, temperature-controlled room 119 
(21 to 25 °C). Participants rested in a supine position for 20 min prior to the initiation of the 120 
FMD measurement. The right arm was extended and supported comfortably on a foam mat. 121 
For the ultrasound, a 12-MHz transducer connected to a Philips CX50 Ultrasound Machine 122 
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was clamped in position over the brachial artery, 5 to 10 cm proximal to the antecubital 123 
crease. After a baseline artery diameter recording of 1 min, a blood pressure cuff placed 124 
around the left forearm was inflated to 200 mmHg. After 5 min the cuff was released, 125 
inducing reactive hyperaemia. The brachial artery image was recorded for 4 min (240 126 
seconds) post-cuff deflation to assess FMD. Images were downloaded for retrospective 127 
analysis. Analysis of FMD was performed using a semi-automated edge detection software 128 
(Vascular Research Tools, Medical Imaging Applications LLC, Coralville IA), which 129 
automatically calculates the brachial artery diameter, corresponding to the internal diameter. 130 
Responses were calculated as the percentage change in brachial artery diameter from 131 
baseline, at 10 second intervals, for 240 seconds after cuff deflation.  132 
Measurement of blood pressure and arterial stiffness 133 
Blood pressure measurements were taken using a Dinamap 1846SX/P oscillometric recorder 134 
(Critikon, Tampa, FL, USA) attached to the non-dominant arm with participants in a seated 135 
position. Following a 10 min rest, one BP measurement was taken immediately prior to 136 
treatment consumption. BP was then measured every 10 min post-treatment consumption for 137 
80 min (9 measurements in total).  138 
Office BP, central diastolic BP, and arterial stiffness were assessed using the SphygmoCor 139 
Xcel (AtCor Medical, Sydney, Australia). Following a 5 min rest in a supine position, BP 140 
measurements were taken on three occasions at 1 min intervals, the first measurement was 141 
discarded and the second and third measurements were averaged. Arterial stiffness was 142 
determined by measuring augmentation Index (AIx) using the Sphygmocor Xcel as described 143 
previously (15) and was standardised to a heart rate of 75 bpm (AIx75).  144 
Cognitive stress test and blood pressure 145 
A selection of cognitive function tests designed to induce cognitive stress using the 146 
Computerised Mental Performance Assessment System (COMPASS, BPNRC, Newcastle 147 
Upon Tyne, UK) was used. This series of tests, described in detail previously (16), comprised 148 
of two computerized serial subtraction tasks (Serial Threes and Serial Sevens) and a Bakan 149 
Rapid Visual Information Processing task (RVIP), each repeated three times. Briefly, for the 150 
Serial Three and Serial Seven subtraction tasks, participants were asked to continuously 151 
subtract three or seven from a random starting number between 800 and 999. This task lasted 152 
for two min and both the number of correct responses and the total number of subtractions 153 
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completed were recorded. For the RVIP task, participants were asked to identify when three 154 
odd or three even digits appeared consecutively in series of single digit numbers presented at 155 
a rate of 100 per min. This task lasted for five min and both the number of correct responses 156 
and the average response time were recorded. Participants rested for 20 min prior to and 15 157 
min after the cognitive testing, which took approximately 30 min. For the duration of this 158 
task (65 min total), blood pressure was measured every 2 min with a Dinamap 1846SX/P 159 
oscillometric recorder (Critikon, Tampa, FL, USA) attached to the non-dominant arm of 160 
participants in a seated position.  161 
Plasma analyses  162 
Plasma samples, obtained 3.5 hrs post-intervention by venepuncture, were collected into 163 
EDTA tubes with added butylated hydroxytoluene and immediately centrifuged at 5000 x g, 164 
at 4°C for 5 min. One 2 mL aliquot of plasma was kept on liquid nitrogen for immediate 165 
analysis of nitrogen oxides (NOx) and the remaining plasma was stored at -80°C until 166 
analysis.  167 
Quercetin metabolites 168 
Plasma quercetin metabolites were measured by liquid chromatography/tandem mass 169 
spectrometry (LCMSMS) as described previously (7). Briefly, plasma (250 µL) collected in 170 
EDTA was incubated for 2 hrs with β-glucuronidase enzyme. As β-glucuronidase has both 171 
glucuronidase and sulfatase activity, but is unable to enzymatically cleave methyl conjugates, 172 
isorhamnetin (O-methylated quercetin) was measured. Following solid phase extraction, 173 
quercetin aglycone and isorhamnetin were measured on a Thermo Scientific TSQ Quantum 174 
Ultra Triple Quadrupole LCMS System (ThermoFisher Scientific, Waltham, MA, USA). 175 
Calibration curves for quercetin and isorhamnetin with the fisetin as the internal standard 176 
were used for quantification.  177 
Measurement of plasma total nitrogen oxides (NOx) 178 
The concentrations of total NOx (nitric oxide, nitros(yl)ated species and nitrite) in plasma 179 
were determined using a previously described gas phase chemiluminescence assay (17). Blood 180 
was collected into N-ethylmaleimide (10 mmol/L) and EDTA (2 mM), mixed and centrifuged 181 
at 3000 x g (5 min, 4°C). Fresh plasma was kept on ice in the dark and analysed within 1 hr. 182 
Antifoam (200 µL) was added prior to injection into the radical purger containing potassium 183 
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iodide (0.125 g) and iodine (0.05 g) in water (2.5 mL) / glacial acetic acid (7.5 mL) at room 184 
temperature. Plasma NOx was quantified by the NO signal peak area of samples against a 185 
nitrite standard (300 µL, 0.5 µM NaNO2
-).  Quantification of NO released by the redox 186 
reactions occurred by its chemiluminescence reaction with ozone using the Nitric Oxide 187 
Analyzer (CLD66, Eco Physics, Sweden). 188 
NO2 and NO3 189 
Nitrate (NO3) and nitrite (NO2) concentrations were measured using gas 190 
chromatography/mass spectrometry (GCMS) as described previously (18), with N15 labelled 191 
NO3 and NO2 internal standards.  192 
Glucose 193 
Plasma glucose was measured using a fully automated analyser (Architect ci8200/c16000 194 
Analyser).  195 
F2-isoprostanes 196 
Systemic oxidative stress was determined by measuring plasma F2-isoprostane concentrations 197 
as described previously (19). Briefly, F2-isoprostane concentrations were calculated in pmol/L 198 
from ratio of the peak areas for the m/z 569 and m/z 573 ions, with a deuterium labelled 199 
internal standard, 8-iso-Prostaglandin F2α-d4. 200 
Statistics 201 
Sample size was calculated with FMD as the primary endpoint. Assuming a within-subject 202 
correlation of r=0.25, 24 pre-intervention measures, 24 post-intervention measures, and a 203 
within group SD of 6%, a sample size of 25 subjects would provide more than 80% power at 204 
alpha=0.05 to detect a difference of 0.85% in FMD. Treatment effects for post-intervention 205 
FMD were obtained using linear mixed models with adjustment for treatment order, the pre-206 
treatment FMD curve, and the time since cuff release with time included as a categorical 207 
variable (0 to 240 seconds at 10 second intervals). In order to allow the treatment effect to 208 
differ over time, we also included a treatment x time interaction term. The subject identifier 209 
was included as a random intercept. Assessment of post-treatment BP was similar to that for 210 
FMD, with time included as a categorical variable (0 to 80 minutes at 10-minute intervals). 211 
When assessing the effect of EMIQ® on the BP during the cognitive stress test, we 212 
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additionally adjusted for the rest-period BP. For all other outcomes, treatment effects were 213 
obtained using linear mixed models with adjustment for treatment order. Statistical analyses 214 
were performed using STATA/IC 14.2 (StataCorp LLC).  215 
 216 
RESULTS: 217 
Baseline data 218 
Recruitment began on 25th September 2017 and the study concluded on 12th June 2018. 219 
Twenty-five participants (12 males, 13 females) completed the study (Figure 1). The baseline 220 
characteristics of the study participants are shown in Table 1.  221 
Endothelial function 222 
Data from one participant was excluded prior to statistical analysis as the clarity of the FMD 223 
image was poor. The observed mean percentages of FMD for 24 participants, between 0 and 224 
240 seconds at 1.5 hrs post-intervention, are presented in Figure 2. Overall, FMD after the 225 
EMIQ® treatment was significantly higher when compared to control [adjusted mean 226 
difference=0.60%, 95% CI: 0.03, 1.17; p=0.040].  227 
Blood pressure and arterial stiffness 228 
Mean systolic BP and diastolic BP, measured immediately before treatment (time=0) and 229 
then every 10 min for 80 min, are shown in Figure 3. There was no significant difference 230 
between EMIQ® and placebo for post-treatment systolic BP (p=0.916) or diastolic BP 231 
(p=0.073). Similarly, there was no difference for MAP (p=0.188) or heart rate (p=0.290). 232 
There was no significant difference between treatments for mean systolic BP, diastolic BP, 233 
central diastolic pressure, MAP, heart rate, or AIx75, measured 2 hrs post-treatment (Table 234 
2).   235 
Cognitive stress test and blood pressure 236 
There were no significant effects associated with the EMIQ® treatment on any of the 237 
cognitive stress test outcomes, nor on BP measurements taken during the cognitive stress 238 
tests (Tables 3 and 4).  239 
10 
 
Plasma analyses 240 
Plasma concentrations of quercetin aglycone and isorhamnetin were significantly higher 241 
(p<0.001) after the ingestion of EMIQ® compared to the placebo (Table 3). There was no 242 
significant difference in plasma glucose, NOx, NO2, NO3, or F2-isoprotanes between EMIQ
® 243 
and placebo treatments.  244 
 245 
DISCUSSION: 246 
This is the first study to investigate the acute effects of an enzymatically-modified 247 
isoquercitrin compound on measures of vascular health, blood pressure and cognitive 248 
function in humans. In this randomised controlled cross-over study, the acute administration 249 
of EMIQ® significantly increased plasma quercetin metabolites and improved endothelial 250 
function. No changes in blood pressure, arterial stiffness, cognitive function, blood pressure 251 
during cognitive stress or biochemical parameters were observed.   252 
In the present study plasma concentrations of quercetin aglycone and isorhamnetin were 253 
significantly higher after the ingestion of EMIQ® compared to the placebo. Previously, the 254 
plasma concentration of conjugated quercetin metabolites has been shown to reach a maximal 255 
level at approximately 1.5 h after intake of EMIQ® (10). For this reason, our primary outcome, 256 
endothelial function, was assessed 1.5 hrs post-intervention.   257 
Endothelial dysfunction, defined as an impairment in endothelium-dependent relaxation, is 258 
implicated in prehypertension, hypertension, atherosclerosis, and stroke (20; 21), and is 259 
associated with an increased risk of cardiovascular disease (22; 23). The results of the present 260 
study suggest that EMIQ® improves postprandial endothelial function. In two previous 261 
studies, acute quercetin administration (1095 mg quercetin aglycone (6); and doses of 262 
quercetin-3-O-glucoside ranging from 50 - 400 mg (7)) had no effect on FMD. In the study by 263 
Larson et al, FMD was measured 10 hrs post-quercetin aglycone administration, the time at 264 
which quercetin metabolites were shown to peak in the plasma (6). The pharmacokinetics of 265 
quercetin aglycones and EMIQ are very different; in the present study FMD was measured 266 
1.5 hrs post-intervention, at the time quercetin metabolites have been shown to peak in the 267 
plasma following EMIQ administration (10). Quercetin-3-O-glucoside has been shown to peak 268 
in the plasma between 1.5 and 3 hrs post-intervention; in our previous study (7), FMD was 269 
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measured 1 hr post-intervention. The differences in study design and the form in which the 270 
quercetin was administered make the direct comparison to the present study difficult. Another 271 
important discrepancy in study design is that EMIQ was administered alongside a meal in the 272 
present study, likely influencing the effect of quercetin on endothelial function (24; 25). Overall, 273 
FMD in the present study was relatively poor as we recruited participants with at least one 274 
risk factor for cardiovascular disease. Although the improvement observed was subtle 275 
(0.66%), if sustained it could have important clinical implications as a 1% increase in FMD is 276 
associated with a 13% lower risk of cardiovascular events (RR: 0.87, 95% CI: 0.83- 0.91) (23).  277 
Evidence suggests that quercetin can improve endothelial health through NO-mediated 278 
vasorelaxant activity as well as through the prevention of oxidant induced endothelial 279 
dysfunction (4). An acute increase in plasma NO status has been observed after both a high-280 
flavonoid apple intervention (17) and quercetin (200 mg) intervention (26). In the present study 281 
we did not observe any increase in plasma NOx, or the end products of NO metabolism, NO3 282 
and NO2. This may have been due to the timing of our blood sample, which was 1.5 hrs after 283 
the measurement of endothelial function, and 3.5 hrs post-intervention. Changes in NO are 284 
likely to be transient, and because of the difficulty in detecting small changes in NO, the 285 
timing of the measurement is likely to be critical.   286 
In our previous randomized clinical trial with healthy men and women, improvements in BP 287 
were also observed with the concomitant increase in nitric oxide status and FMD, after intake 288 
of flavonoid-rich apples (17). In a meta-analysis of randomized controlled trials, significant 289 
reductions in both systolic BP (−3.04 mm Hg, 95% CI: −5.75, −0.33, p=0.028) and diastolic 290 
BP (−2.63 mm Hg, 95% CI: −3.26, −2.01, p<0.001) were seen following quercetin 291 
supplementation (27). Furthermore, in spontaneously hypertensive rats, EMIQ® administered 292 
at a dose of 26 mg/kg/d suppressed the increase in systolic BP more effectively than 293 
quercetin aglycone (12). In the present study we observed no effect of EMIQ® on post-294 
treatment BP nor on BP during the cognitive stress test. This lack of effect may be due to the 295 
dose given; in the aforementioned meta-analysis there was only a significant effect on BP 296 
when quercetin was administered at doses greater than 500 mg/day (27). Additionally, the 297 
health status of the participants may have played a role as a decrease in systolic BP following 298 
quercetin supplementation is generally seen in hypertensive individuals (28; 29; 30), not in pre-299 
hypertensive or normotensive individuals (6; 30; 31; 32; 33; 34).  300 
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Many functions of the endothelium are affected under oxidative stress, including endothelial 301 
cell apoptosis (35) and adhesion of inflammatory cells (36), initiating the development of 302 
atherosclerosis. Quercetin may decrease oxidative stress through the stimulation of protective 303 
defences and repair systems (37). In apolipoprotein E (apoE)–deficient atherogenic mice, 304 
EMIQ® supplementation for 14 weeks significantly suppressed aortic and aortic sinus 305 
atherosclerotic lesion areas and decreased levels of 4-hydroxy-2-nonenal, a marker of 306 
oxidative stress (13). In the present study we observed no acute changes in levels of plasma F2-307 
isoprostanes, an in vivo biomarker of oxidative stress, following the EMIQ® intervention. It 308 
may be that long-term interventions are required to observe changes in biomarkers of 309 
oxidative stress. Evidence that quercetin may impede the development of CVD by 310 
moderating oxidative stress is stronger in animal studies than human studies (4).  311 
There is evidence that flavonols, the flavonoid subclass to which quercetin belongs, can 312 
reduce the risk of type 2 diabetes (T2D). This comes from an observational study which 313 
found that each 2.5- fold increase in flavonol intake was associated with a 26% lower 314 
incidence of T2D (38), and a meta-analysis demonstrating a significant reduction in fasting 315 
plasma glucose (difference in mean = −0.18 mmol/L; 95% CI: −0.29, −0.08), following 316 
flavanol intake (39). However, fasting plasma glucose was not significantly lower in any of the 317 
studies with a quercetin intervention. In the present study we saw no acute effect of EMIQ® 318 
on plasma glucose. Given that the study population was relatively normoglycemic, this may 319 
be better investigated in a hyperglycemic population.  320 
Evidence that quercetin can improve cognitive function comes wholly from animal studies (40; 321 
41; 42). To our knowledge this is the first study to examine the acute effects of a quercetin 322 
derivative on cognitive function in humans. We saw no significant effects of EMIQ® on any 323 
measures of cognitive function in the present study. This warrants further investigation; 324 
future studies could consider a long-term intervention and a broader range of cognitive 325 
function measurements.  326 
Strengths of the present study are that any inter-subject variability was accounted for by our 327 
cross-over study design and adjustments for baseline measurements of FMD controlled for 328 
day to day variability. There are, however, several limitations: firstly, only the primary 329 
outcome was measured before and after the intervention. Secondly, the study was only 330 
powered to detect a change in the primary outcome meaning that we may have been 331 
underpowered to detect changes in secondary outcomes. So as not to affect the measurement 332 
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of any other outcomes, the blood sample was taken 1.5 hrs after the measurement of FMD 333 
(3.5 hrs post-intervention). Additionally, this study only investigated one dose of EMIQ®, 334 
with the primary outcome measured at only one time-point. 335 
In this human intervention study, the acute administration of EMIQ® significantly increased 336 
circulating quercetin metabolites and improved postprandial endothelial function. The 337 
addition of EMIQ® to commercially available foods and beverages may have positive effects 338 
on vascular function. The potential health benefits associated with regular consumption 339 
warrants investigation in longer term randomised controlled trials.  340 
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TABLES 
Table 1. Baseline characteristics of study participants 
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Characteristic Mean ± SD 
Age (years) 64.1 ± 6.3 
Weight (kg) 77.6 ± 14.9 
BMI (kg/m
2
) 27.0 ± 3.7 
Systolic BP (mmHg) 128.6 ± 15.3 
Diastolic BP (mmHg) 73.6 ± 8.4 
Total cholesterol (mM) 5.6 ± 1.0 
Triglyceride (mM) 1.0 ± 0.3 
Low- density lipoprotein cholesterol (mM) 3.7 ± 0.8 
High-density lipoprotein cholesterol (mM) 1.5 ± 0.4 
Fasting plasma glucose (mM)  5.2 ± 0.5 
Creatinine (mM) 67.9 ± 10.3 
eGFR (mL/min/1.73 m
2
) 86 ± 7.2 
n=25; males=12, females=13 
BP, blood pressure.   
 
 
 
Table 2. Pulse wave analysis  
 EMIQ® Control p-value 
Systolic BP (mmHg) 129.3 ± 3.2 130.9 ± 3.2 0.489 
Diastolic BP (mmHg) 73.8 ± 1.8 74.1 ± 1.8 0.702 
Central DP (mmHg) 74.3 ± 1.8 75.0 ± 1.8 0.518 
MAP (mmHg) 88.9 ± 2.1 89.8 ± 2.1 0.455 
HR (bpm) 55.9 ± 1.7 57.3 ± 1.7 0.281 
AIx75 (%) 13.9 ± 2.0 13.2 ± 2.0 0.635 
Results are presented as means ± sd (n=25). P-values for treatment effect were 
obtained using linear mixed models with adjustment for treatment order. BP, 
blood pressure; MAP, mean arterial pressure; PR, pulse rate.  
Table 3. Cognitive function measurements 
 EMIQ® Control p-value 
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Serial 3 subtractions total  25.1 ± 9.0 25.2 ± 9.7 0.710 
Serial 3 subtractions correct  27.0 ± 8.7 26.8 ± 9.4 0.701 
Serial 7 subtractions total  19.1 ± 7.1 18.6 ± 7.9 0.569 
Serial 7 subtractions correct  16.3 ± 7.7 16.4 ± 7.7 0.595 
RVIP correct 54.1 ± 22.5 53.5 ± 22.4 0.299 
RVIP response time (msec) 559.8 ± 57.8 551.8 ± 56.9 0.210 
Cognitive test measurements, 2.5 hours post consumption of EMIQ® or placebo 
treatment. Results are presented as means ± sd (n=23). P-values for treatment 
effect were obtained using linear mixed models with adjustment for treatment 
order and time.  
 
 
 
 
Table 4. Blood pressure during cognitive stress testing 
 EMIQ® Control p-value 
Systolic BP (mmHg) 129.8 ± 18.0 125.2 ± 19.9 0.468 
Diastolic BP (mmHg) 72.1 ± 10.1 73.3 ± 14.4 0.510 
MAP (mmHg) 94.8 ± 12.4 93.4 ± 15.0 0.466 
PR (bpm) 63.3 ± 10.1 65.8 ± 15.6 0.728 
Results are presented as means ± sd (n=25). Blood pressure was measured every 2 
minutes for 34 minutes (17 measures total). P-values for treatment effect were 
obtained using linear mixed models with adjustment for treatment order, time and 
blood pressure during pre-test rest period. BP, blood pressure; MAP, mean arterial 
pressure; PR, heart rate.  
 
 
 
Table 5. Plasma analyses 
 EMIQ® Control p-value 
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Glucose (mmol/L) 4.7 ± 0.1 4.7 ± 0.1 0.994 
NOx (nM NO
2
) 36.1 ± 6.8 36.3 ± 7.1 0.979 
NO
3
 (µM) 29.9 ± 1.8 30.9 ± 1.8 0.587 
NO
2
 (µM) 2.5 ± 0.2 2.8 ± 0.2 0.263 
F
2
-Isoprostanes (pmol/L) 540.7 ± 33.5 517.2 ± 33.5 0.510 
Quercetin aglycone (nM) 144.9 ± 12.3 12.6 ± 12.3 <0.001 
Isorhamnetin (nM) 245.5 ± 16.5 41.7 ± 16.5 <0.001 
Measurements of plasma glucose, NOx, nitrate (NO
3
), nitrite (NO
2
), F
2
-
isoprostanes, and quercetin metabolites, 3 hours post consumption of EMIQ® or 
placebo treatment. Results are presented as means ± sd (n=25). P-values for 
treatment effect were obtained using linear mixed models with adjustment for 
treatment order. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
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Figure 1. Participant flow diagram. 
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Figure 2. Acute changes in flow-mediated dilatation (FMD) over 240 s measured 1.5 h post-
intervention. Results are presented as means (n=24). P-values for treatment effect were 
obtained using linear mixed models with adjustment for treatment order, time, and baseline 
(pre-treatment) FMD. Over the time course there was a significant difference between 
interventions (p=0.040). EMIQ®, Enzymatically-Modified Isoquercitrin.  
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Figure 3. Acute changes in systolic and diastolic blood pressure over 80 minutes 
immediately post-intervention. Treatment was given immediately after the first measurement 
at time=0. Results are presented as means ± sd error bars (n=25). P-values for treatment 
effect were obtained using linear mixed models with adjustment for treatment order and time. 
Over the time course there was no significant difference between interventions (systolic, 
p=0.916; diastolic, p=0.073). EMIQ®, Enzymatically Modified Isoquercitrin. 
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